Table 1.
Demographics of the participating cohorts.
| Variable | vaccine-CD20-vaccine cohort (n = 4) | CD20-vaccine cohort (n = 11) | p-value |
|---|---|---|---|
| age, y mean ± SD | 35.0 ± 11.4 | 49.8 ± 9.5 | 0.025 |
| female% | 55% | 50% | n.s. |
| EDSS, median (IQR) | 2.25 (1.75–3.5) | 5.5 (3.75–6.5) | 0.006 |
| No. cycles, median (range) | 1 (1–2) | 5.0 (2–7) | 0.0015 |
| MS duration, y mean ± SD | 5.75 ± 6.2 | 11.2 ± 8.2 | n.s. |
| No. IMDs, mean ± SD | 2.25 ± 2.6 | 1.1 ± 1.2 | n.s. |
y = years; SD = standard deviation; EDSS = expanded disability status scale; IQR = interquartile range; No. = number; nr. cycles = number of anti-CD20 infusions received; MS = multiple sclerosis; No. IMDs = immunomodulating drugs before anti-CD20 medication; n.s. = statistically not significant.